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Abstract
Problem/Condition: In the United States, diabetes mellitus is the most important
cause of lower-extremity amputation and end-stage renal disease; the major cause of
blindness among working-age adults; a major cause of disability, premature mortality,
congenital malformations, perinatal mortality, and health-care costs; and an important
risk factor for the development of many other acute and chronic conditions (e.g., dia-
betic ketoacidosis, ischemic heart disease, stroke). Surveillance data describing
diabetes and its complications are critical to increasing recognition of the public
health burden of diabetes, formulating health-care policy, identifying high-risk groups,
developing strategies to reduce the burden of this disease, and evaluating progress in
disease prevention and control.
Reporting Period Covered: In this report, data are summarized from CDC’s diabetes
surveillance system; trends in diabetes and its complications are evaluated by age,
sex, and race for the years 1980–1989.
Description of System: CDC has established an ongoing and evolving surveillance
system to analyze and compile periodic, representative data on the disease burden of
diabetes and its complications in the United States. Data sources currently include
vital statistics, the National Health Interview Survey, the National Hospital Discharge
Survey, and Medicare claims data for end-stage renal disease.
*All the authors, with the exception of Dr. Eberhardt, were affiliated at the time of this report
with the Division of Diabetes Translation, National Center for Chronic Disease Prevention and
Health Promotion.  Dr. Eberhardt was affiliated with the Office of Analysis and Epidemiology,
National Center for Health Statistics.
Vol. 42 / No. SS-2 1
Results and Interpretation: In 1989, approximately 6.7 million persons in the United
States reported that they had diabetes mellitus, and a similar number probably had
this disabling chronic disease without being aware of it. The disease burden of diabe-
tes and its complications is large and is likely to increase as the population grows
older. Effective primary, secondary, and tertiary prevention strategies are needed, and
these efforts need to be intensified among groups at highest risk, including blacks.
Important gaps exist in periodic and representative data for describing the disease
burden.
Actions Taken: CDC is assisting diabetes control programs in 26 states and one terri-
tory. These programs attempt to reduce the burden of diabetes by preventing
blindness, lower-extremity amputations, cardiovascular disease, and adverse out-
comes of pregnancy among persons with diabetes. Because of important limitations
in measuring the burden of diabetes, CDC is  exploring sources of surveillance data for
blindness, adverse outcomes of pregnancy, and the public health burden of diabetes
among minority groups.
INTRODUCTION
In the United States, diabetes mellitus is the most frequent cause of blindness
among working-age adults; the most important cause of nontraumatic lower-extrem-
ity amputation (LEA) and end-stage renal disease (ESRD); a major cause of congenital
malformations, perinatal mortality, disability, premature mortality, and increased
health-care costs; and an important risk factor for the development of many other
acute (e.g., diabetic ketoacidosis [DKA]) and chronic conditions (e.g., ischemic heart
disease [IHD], stroke) (1–3 ). Diabetes and its complications shorten life span, limit
normal daily activities, create disability, increase use of health-care services, and im-
pose an economic burden on persons who have the disease.
Surveillance data describing the magnitude of the disease burden of diabetes and
its complications can be used to identify high-risk groups, develop strategies to re-
duce the burden associated with diabetes, help formulate health-care policy, and
evaluate progress in disease prevention and control. CDC has established an ongoing
diabetes surveillance system to compile and analyze periodic, representative data on
the disease burden associated with diabetes and its complications in the United
States. Data sources for the surveillance system include vital statistics, the National
Health Interview Survey (NHIS), the National Hospital Discharge Survey (NHDS), and
Medicare claims data. These data are analyzed to estimate diabetes incidence, preva-
lence, mortality, DKA, ESRD, cardiovascular disease (CVD), LEA, hospitalization, and
disability. The results of these analyses for the period 1980-1989 are summarized in
this report and presented in greater detail in Diabetes Surveillance, 1991.*
*Diabetes Surveillance, 1991 is the second report from CDC’s diabetes surveillance system. A
copy of this report is available from the National Center for Chronic Disease Prevention and
Health Promotion, Rhodes-1113, MS-K13, Centers for Disease Control and Prevention, 4770
Buford Highway, N.E., Atlanta, GA 30341–3724.
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DATA ANALYSIS
For this report, trends were evaluated in diabetes and its complications by age, sex,
and race. The presentation of results was generally limited to specific subgroups for
which relatively stable estimates could be obtained. In most circumstances, race-spe-
cific results were evaluated only for whites and blacks because the number of persons
in the sample surveys analyzed was not sufficient for stable estimates to be calculated
for other racial groups.
Diabetes incidence and prevalence rates and some diabetes mortality rates were
calculated by using estimates of the resident population of the United States as the
denominator. These rates were standardized by age according to the direct method,
with the 1980 United States resident population as the standard population. LEA and
ESRD incidence, disability prevalence, rates of hospital discharge, and some mortality
rates were calculated by using estimates of the number of persons known to have
diabetes as the denominator. These rates for diabetic populations indicate the risk of
various complications among persons with diabetes and are useful for comparing
complication rates among subgroups of persons with diabetes. Rates for the diabetic
population were age standardized according to the direct method, with the 1980
United States population of persons with diabetes as the standard population.
Most of the data are based on samples of the population and are thus estimates,
with margins of error due to both sampling and nonsampling error. Because of these
margins of error, estimates may fluctuate from year to year.
DATA SOURCES
Incidence and Prevalence Data
Data Source: National Health Interview Survey
The incidence and prevalence of self-reported diabetes were determined from the
1980–1989 NHIS, conducted by CDC’s National Center for Health Statistics (NCHS).
The NHIS, which has been conducted since 1957, is an annual household survey of
approximately 120,000 civilian, noninstitutionalized United States residents. The sur-
vey provides information on the health of the United States population, including
information on the prevalence and incidence of disease, the extent of disability, and
the utilization of health-care services. The NHIS has a multistage probability design
(4).
Each year, a one-sixth subsample of NHIS respondents is asked whether anyone in
the family has had diabetes in the past 12 months. If a household member has diabe-
tes, the date of diagnosis is ascertained. In this report, diabetes prevalence was
defined as the number of persons with diabetes. Diabetes incidence was defined as
the number of persons who were diagnosed within the previous 12 months. Three-
year moving averages were used to improve the precision of all estimates of
incidence and of prevalence estimates among blacks.
Data Limitations: The NHIS underestimates the true prevalence of diabetes. About
half of persons with diabetes are not aware that they have the disease (5 ). NHIS proxy
respondents (i.e., household members responding for absent adult members) are also
likely to underreport diabetes (5 ). In addition, the NHIS sample does not include per-
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sons in institutional settings, who are more likely to have diabetes than are noninsti-
tutionalized persons.
Mortality Data
Data Source: Multiple-Cause-of-Death Data
NCHS compiles and codes information on all deaths in the United States and re-
leases annual multiple-cause-of-death data tapes. Data on these tapes include
decedents’ age, race, sex, and state of residence; the underlying cause of death; and
contributing causes of death. Up to 20 causes of death for each decedent are coded
according to the International Classification of Diseases, Ninth Revision (ICD–9).
Data tapes for the years 1980–1988 were used to extract information on deaths
associated with diabetes (ICD-9 code 250) and to examine trends in diabetes as the
underlying cause of death and as any listed cause of death. Among deaths for which
diabetes was a listed cause, the analysis also examined deaths for which the corre-
sponding underlying cause was DKA (ICD-9 code 250.1), major CVD (ICD-9 390–448),
IHD (ICD-9 codes 410–414), or stroke (ICD-9 codes 430–434, 436–438).
Data Limitation: Diabetes is underreported on death certificates. Among persons
known to have diabetes, only about 40% have diabetes listed as a cause of death and
only 10% have diabetes recorded as the underlying cause of death (6,7 ). However,
since underreporting is consistent over time and does not vary by race and sex, differ-
ences in temporal trends and relative differences between these groups are not likely
to be attributable to reporting artifacts (8 ).
Hospitalization Data
Data Source: National Hospital Discharge Survey 
Data from the 1980–1988 NHDS (9 ), also conducted by CDC’s NCHS, were used to
estimate diabetes-related hospital discharges. NHDS collects data on hospital dis-
charges from a sample of short-stay, nonfederal hospitals in the United States. Data
collected include information on patients’ age, race, sex, and length of stay, up to
seven diagnoses (one primary and six secondary diagnoses), and four surgical proce-
dures.
The analysis estimated hospital discharges for which diabetes was the primary di-
agnosis (ICD-9 code 250) and for which diabetes was listed as any diagnosis. Among
discharges with diabetes as a secondary diagnosis, discharges for which the primary
diagnosis was DKA (ICD-9 code 250.1), major CVD (ICD-9 390–448), IHD (ICD-9 codes
410–414), or stroke (ICD-9 codes 430–434, 436–438) were estimated.
NHDS data were also used to examine the incidence of LEA. Incident cases were
defined as discharges having diabetes as a listed diagnosis and an LEA (ICD-9 proce-
dure code 84.1). Discharges with traumatic amputation procedural codes (ICD-9
procedure codes 895–897) were excluded.
Data Limitation: Hospitalizations related to diabetes may be underestimated by ap-
proximately 40% (10 ). Since NHDS samples hospital discharges and not persons,
NHDS hospital discharge rates for diabetes-related diseases and procedures are influ-
enced by persons who are hospitalized more than once for the same condition and
hence may be sampled more than once.
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End-Stage Renal Disease Data
Data Source: Management and Medical Information System, ESRD Program, Bu-
reau of Data Management and Strategy, Health Care Financing Administration
ESRD is renal insufficiency requiring dialysis or kidney transplantation for survival.
Because >90% of ESRD treatment in the United States is reimbursed by Medicare’s
ESRD program, 1980–1989 data from Medicare’s medical information system were
used to examine the incidence of ESRD attributed to diabetes mellitus (ESRD-DM).
ESRD-DM incidence was defined as cases  for which treatment was initiated for ESRD
and for which diabetes was the primary cause of renal failure.
Data Limitations: Because ESRD-DM incidence was defined in terms of initiation of
ESRD treatment, changes in incidence may be due to changes both in disease inci-
dence and treatment practices. The latter may be influenced by changes in treatment
availability and in the definition of treatment eligibility (11 ). In addition, the ascertain-
ment of incident cases was incomplete, since Medicare reimburses only about 90% of
ESRD treatment.
Disability Data
Data Source: National Health Interview Survey
Indicators of disability among persons with diabetes were derived from the
1983–1989 NHIS. Two of the major indicators of disability used in the NHIS are activity
limitation and activity restriction. Activity limitation reflects a long-term reduction in
activity resulting from one or more chronic diseases or impairments. Reduction in
activity is measured in terms of activities normal for a person’s age and sex group:
“ordinary play” for children <5 years of age, “going to school” for children 5–17 years
of age, “working at a job or business” or “keeping house” for persons 18–69 years of
age, and independent performance of basic life activities (e.g., bathing, eating, shop-
ping) for persons ≥70 years of age. Persons can be categorized as being a) unable to
perform their major activity, b) able to perform their major activity but limited in the
kind or amount of this activity, c) not limited in major activity but limited in other ac-
tivities, and d) not limited in activity. This analysis examined persons unable to
perform major activity (category a), limited in major activity (categories a–b), and lim-
ited in activity (categories a–c). Three-year moving averages were used to improve
precision of the estimates.
The other major indicator of disability used in NHIS is activity restriction. This indi-
cator refers to a reduction in activity due to either short-term or long-term conditions.
Activity restriction is measured as school-loss days (for children ages 5–17), work-loss
days (for currently employed persons ages 18–69), restricted-activity days (days in
which persons limit their usual activities), and bed-rest days (inpatient hospital days
and days in which a person stayed in bed for more than half a day because of illness
or injury). The total number of restricted-activity days is the total number of days that
a person experiences at least one of the above types of days. Because of small sample
sizes, this analysis presents data in 3-year moving averages for total restricted-activity
days and bed-rest days only.
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Data Limitations: Although NHIS provides a stable source of annual estimates of
disability, it does not sample the institutionalized United States population. Therefore,
estimates of disability derived from NHIS underestimate the total amount of disability
associated with diabetes.
Because NHIS changed the way it measured disability indicators in 1982, analysis
of these indicators was limited to the years 1983–1989.
Population Data
Data Sources:1980 Census estimates, 1981–1989 intercensal estimates, and Na-
tional Health Interview Survey
Census estimates for 1980 and intercensal estimates for subsequent years were
used to calculate rates (12 ). Estimates of the diabetic population (derived from NHIS)
were used to calculate rates among persons with diabetes.
Data Limitations: For limitations of NHIS, see the above discussion of limitations
under Incidence and Prevalence Data.
RESULTS
Prevalence and Incidence of Diabetes
In 1989, about 6.7 million persons in the United States (2.7% of the population)
reported that they had diabetes. Although the prevalence of diabetes has increased
since 1959, the overall rate of increase in the 1980s has slowed and reached a plateau
(Table 1). Diabetes prevalence as estimated from NHIS data increased by 67% from
1959 through 1966, by 41% from 1966 through 1973, by 21% from 1973 through 1980,
and by 4% from 1980 through 1989.
During the 1980s, the age-standardized prevalence of diabetes was higher among
blacks than whites (Figure 1). Black males were the only group to show a marked
increase (28%) in prevalence during the period 1980–1989. In 1989, the age-stand-
ardized prevalence of diabetes among blacks, regardless of sex, was approximately
twice that for whites.
The number of new diabetes cases (i.e., diabetes incidence) averaged 648,000 per
year. The incidence of diabetes increased in the early 1980s and then reached a pla-
teau (Table 2). The lowest rates occurred among persons <45 years of age.
Mortality
Diabetes Mortality in the General Population
The annual number of deaths for which diabetes was listed as the underlying cause
increased from 34,851 in 1980 to 40,368 in 1988. From 1982 through 1988, the age-
standardized mortality rates for both black males and black females increased (by 23%
and 11%, respectively) (Figure 2). The rates for white males and white females re-
mained relatively constant.
The annual number of deaths for which diabetes was listed as any cause of mortal-
ity (diabetes-related deaths) increased from 135,931 in 1980 to 157,265 in 1988.
Race-sex temporal trends in age-standardized diabetes-related mortality were similar
to those for diabetes as an underlying cause; mortality increased 21% among black
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1980 1981 1982 1983 1984 1985 1986 1987 1988 1989
  ≤44 Number* 1,010   952   984 1,002   994 1,038 1,047 1,364 1,092 1,224
Rate   6.4   6.0   6.1   6.2   6.1   6.3   6.3   8.1   6.4   7.2
45–46 Number 2,389 2,545 2,567 2,600 2,360 2,331 2,849 2,553 2,460  2,707
Rate  53.7  57.1  57.6  58.2  52.7  51.9  63.2  56.4  53.5  58.2
65–74 Number 1,522 1,364 1,525 1,304 1,756 1,849 1,592 1,703 1,704 1,632
Rate  97.3  85.8  94.2  79.1 105.0 108.9  91.9  96.4  95.2  89.8
  ≥75 Number  861   948   810   874 1,090 1,101 1,284 1,195 1,094 1,096
Rate  85.7  91.8  76.3  80.0  97.1  95.5 108.6  98.2  87.8  85.7
Total Number 5,782 5,809 5,886 5,781 6,200 6,320 6,771 6,815 6,350 6,659
Rate  25.4  25.1  25.2  24.5  25.9  26.2  27.8  27.7  25.6  26.6
Age-adjusted rate  25.4  25.3  25.4  24.7  26.0  26.2  27.9  27.6  25.4  26.3
*In thousands.

















FIGURE 1. Age-standardized prevalence* of diabetes, by race, sex, and year — United
States, 1980–1989
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FIGURE 2. Age-standardized mortality* for diabetes as underlying cause of death,
by race, sex, and year — United States, 1980–1988





1980 1981 1982 1983 1984 1985 1986 1987 1988 1989
  ≤44 Number†  179  149  218  159  169  151  218  226  265  256
Rate 1.07 1.18 1.11 1.14 0.99 1.10 1.21 1.35 1.50 1.56
45–64 Number  190  243  367  363  319  294  260  215  256  335
Rate 4.94 6.07 7.34 7.91 7.34 6.54 5.73 5.29 5.90 6.45
  ≥65 Number  172  103  128  168  145  235  165  290  156    86
Rate 5.65 5.44 5.25 5.68 6.91 6.73 8.34 8.18 6.18 4.18
Total Number  541  495  713  690  833  879  644  731  678  677
Rate 2.34 2.61 2.79 2.96 2.88 2.79 2.90 2.89 2.89 2.80
Age-adjusted rate 2.35 2.62 2.80 2.98 2.90 2.80 2.90 2.89 2.89 2.81
*Three-year moving average.
† In thousands.
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males (from 77.7 to 89.4 per 100,000) and 15% among black females (from 94.5 to
102.0 per 100,000). Diabetes-related mortality rates remained relatively constant for
white males and white females.
From 1980 through 1988, diabetes-related mortality rates and mortality rates for
diabetes as an underlying cause of death increased with age; the highest rates oc-
curred among persons ≥85 years of age.
Diabetes Mortality in the Diabetic Population
When age-standardized mortality rates were calculated by using the number of
persons known to have diabetes as the denominator, race-sex trends in age-stand-
ardized mortality were less clear. Age-standardized rates for diabetes as the
underlying cause of death were lower in 1988 than in 1980 for white males, black
males, and black females (Figure 3). White females were the only group whose rates
were higher in 1988 than in 1980. Of the four race-sex groups examined, black males
had the highest age-standardized rates.
Race-sex trends for diabetes-related mortality rates were similar to those for diabe-
tes as the underlying cause of death. The highest age-standardized rates occurred
among white males.
Hospitalizations
In 1988, diabetes was the primary diagnosis for 454,000 hospital discharges; it oc-
curred as any one of seven listed diagnoses for 2.8 million hospital discharges.
Age-standardized rates of hospital discharges for which diabetes was listed as the
primary diagnosis increased slightly from 1980 through 1983 but then decreased and
reached a plateau (Table 3). Age-specific rates were highest among persons <45 years
of age. The next highest rates were found among persons ≥75 years of age. The age
groups of 45–64 years and 65–74 years had similar rates, which were the lowest in the
analysis. Age-standardized rates were higher for blacks than whites, and black males
had the highest rates (Figure 4).
In general, the diabetic population’s age-standardized rates of hospital discharges
that listed diabetes as a primary or secondary diagnosis showed temporal trends simi-
lar to those for diabetes as a primary diagnosis. However, age-specific rates increased
with age. Among black females with diabetes, age-standardized rates increased 27%
from 1983 through 1988 (from 324 to 411 per 1,000).
Cardiovascular Disease
In 1988, more than half of all diabetes-related deaths had major CVD listed as the
underlying cause (n=80,876). Of these deaths from CVD, 61% (n=49,433) were attribut-
able to IHD and 14% (n=11,653) to stroke. Age-specific rates for these diseases
increase dramatically with age (Table 4). Among persons with diabetes, age-stand-
ardized mortality rates attributable to CVD, IHD, and stroke were lower in 1988 than in
1980; most of the decline occurred from 1983 through 1984. The declines for these 2
years were apparent among persons with diabetes who were ≥65 years of age. CVD
mortality among persons with diabetes who were <45 years of age tended to increase
rather than decrease.
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*Per 100,000 persons with diabetes.
FIGURE 3. Age-standardized mortality* for diabetes as underlying cause of death
among persons with diabetes, by race, sex, and year — United States, 1980–1988
TABLE 3. Hospital discharge rate for diabetes as primary diagnosis per 1,000 persons
with diabetes, by age group and year — United States, 1980-1988
Year
Age (years) 1980 1981 1982 1983 1984 1985 1986 1987 1988
  ≤44 156.7 175.1 183.0 182.4 167.3 144.0 145.7 115.7 140.1
45–64 102.5  93.8  93.9  91.1  84.3  68.4  55.9  58.8  54.6
65–74  90.3 105.5  94.8 112.0  73.8  51.8  67.4  54.1  53.3
  ≥75 121.4 111.6 117.8 124.8  89.6  68.1  56.2  61.8  69.2
Total 111.6 112.8 112.3 116.7  95.6  75.9  72.5  69.5  71.5
Age-adjusted
rate 111.6 113.7 113.3 117.5  96.8  77.2  74.6  67.9  71.3
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*Per 1,000 persons with diabetes.
FIGURE 4. Age-standardized rate* of hospital discharge with diabetes as primary
diagnosis among persons with diabetes, by race, sex, and year — United States,
1980–1988
TABLE 4. Mortality from major cardiovascular disease, ischemic heart disease, and
stroke as underlying cause of death among persons with diabetes, per 100,000
diabetic population, by age group and year — United States, 1980–1988
Year
Age (years) 1980 1981 1982 1983 1984 1985 1986 1987 1988
Major cardiovascular disease
  ≤44    82.6    90.3    87.3    95.3   106.3    95.9   106.1    83.5   102.6
45–64   624.9   597.4   579.4   586.4   646.1   657.0   533.8   591.8   602.1
65–74 1,512.5 1,669.3 1,502.1 1,813.7 1,360.3 1,318.2 1,502.3 1,440.5 1,421.4
  ≥75 4,273.2 3,820.6 4,566.4 4,407.8 3,560.0 3,571.6 3,106.7 3,341.9 3,721.7
Total 1,307.3 1,291.9 1,285.3 1,356.1 1,274.2 1,266.3 1,183.4 1,184.1 1,273.6
Age-adjusted rate 1,307.1 1,270.9 1,330.0 1,392.7 1,173.7 1,167.0 1,097.2 1,136.1 1,195.2
Ischemic heart disease
  <44    50.1    53.5    57.4    58.3    64.1    59.1    64.1    48.1    57.7
45–64   437.3   413.1   405.0   405.0   437.7   437.7   350.2   384.7   385.5
65–74 1,017.4 1,112.5 1,024.3 1,207.9   905.7   869.7   981.7   935.3   917.8
  ≥75 2,522.6 2,270.8 2,709.0 2,631.6 2,097.5 2,104.5 1,831.4 1,941.1 2,164.3
Total   833.0   821.5   824.6   862.8   802.2   792.4   735.4   727.7   778.4
Age-adjusted rate   832.9   811.0   850.4   887.3   742.8   733.5   687.0   702.7   733.3
Stroke
  <44     8.6    10.7     6.9    10.2    10.9     9.9     8.9     7.2     9.2
45–64    68.2    62.3    59.0    56.5    66.4    63.5    54.4    57.5    59.4
65–74   224.0   249.0   197.1   250.3   179.2   176.1   195.5   178.1   175.0
  ≥75   883.4   743.1   881.8   815.2   666.4   643.3   541.1   593.6   649.6
Total   220.2   208.7   199.4   206.9   194.9   188.7   172.9   171.5   183.5
Age-adjusted rate   220.2   203.8   208.8   212.4   175.7   170.1   156.1   160.3   169.0
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Of the four race-sex groups examined, white males had the highest age-stand-
ardized mortality rates for major CVD (Figure 5). Rates for black males, however,
exceeded those for white males among persons <45 years of age. Although the age-
standardized rates for white females were higher than those for black females, black
females <65 years of age had higher rates than white females.
In 1988, 33% (908,000) of all diabetes-related hospitalizations listed major CVD as
the primary diagnosis. Of these hospitalizations for CVD, 43% (n=386,000) were for
IHD and 13% (n=114,000) were for stroke. Hospital discharge rates for major CVD and
IHD among persons with diabetes increased from 1980 through 1988 (Figure 6). Al-
though the trend for stroke was less clear, the rate was higher in 1988 than in 1980. In
1988, the age-standardized hospital discharge rates were 40% higher for major CVD,
42% higher for IHD, and 29% higher for stroke than in 1980. In general, hospital dis-
charge rates for major CVD, IHD, and stroke increased with age. The rates of increase
for major CVD and IHD were greater among persons <45 years of age.
Nontraumatic Lower-Extremity Amputation
In 1988, 55,000 hospital discharges with LEA were reported among persons with
diabetes (Table 5). This number represented approximately half of all hospital dis-
charges with LEA. The incidence of LEA among persons with diabetes was relatively
stable from 1980 through 1982, increased dramatically in 1983, and then leveled off
(Table 5). Rates for LEA increased with age (Table 5) and were higher among males
than among females and among blacks than among whites (Figure 7).














*Per 100,000 persons with diabetes.
FIGURE 5. Age-standardized mortality* for major cardiovascular disease as underlying
cause of death among persons with diabetes, by race, sex, and year — United States,
1980–1988
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*Per 1,000 persons with diabetes.
FIGURE 6. Age-standardized rate* of hospital discharge for major cardiovascular
disease (CVD), ischemic heart disease (IHD), and stroke as primary diagnosis among
persons with diabetes, by year — United States, 1980–1988
TABLE 5. Number of discharges for nontraumatic lower-extremity amputation and
hospital discharge rate per 1,000 persons with diabetes, by age group and year —
United States, 1980–1988
Year
Age (years) 1980 1981 1982 1983 1984 1985 1986 1987 1988
  ≤44 Number*    2    2    2    3    2    4    2    3    3
Rate  1.6  1.6  1.6  2.8  2.4  4.2  2.3  2.1  2.5
45–64 Number   11   10   10   16   17   19   15   15   20
Rate  4.7  3.8  3.9  6.1  7.2  8.1  5.4  5.8  8.0
65–74 Number   12    9    9   17   14   16   17   20   13
Rate  7.6  6.4  6.0 13.1  8.0  8.6 10.5 12.0  7.5
  ≥75 Number   12   10   10   12   14   14   13   18   20
Rate 13.5 10.5 12.6 13.2 12.9 12.4 10.2 14.8 18.0
Total Number   36   30   31   47   47   53   48   56   55
Rate  6.3  5.1  5.3  8.2  7.6  8.4  7.1  8.2  8.6
Age-adjusted rate  6.3  5.1  5.4  8.4  7.4  8.2  6.9  8.1  8.4
*In thousands.
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Diabetic Ketoacidosis
In 1988, DKA was the primary diagnosis for 84,000 hospital discharges. The age-
standardized rates of hospital discharge for DKA increased from 1980 through 1984,
decreased slightly in 1985, and then reached a plateau (Table 6). DKA hospital dis-
charge rates were highest among persons <45 years of age. Among the race-sex
groups examined, rates were higher among black males, followed by black females,
white females, and white males. In 1988, the rate for black males was more than three
times the rate for white males (26.8 vs. 7.9 per 1,000 diabetic population).
In 1988, DKA was listed as the underlying cause of 1,905 deaths. During the period
1980–1987, DKA mortality declined from 30.6 to 23.2 per 100,000 diabetic population.
The rate then increased in 1988 to 27.7 per 100,000 persons with diabetes. The highest
DKA mortality rates were among persons ≥75 years of age, followed by persons <45
years of age. Among the race-sex groups examined, age-standardized mortality rates
were highest among black males, followed by black females and then by whites, with
little difference between the sexes (Figure 8).
End-Stage Renal Disease
The number of new cases of ESRD-DM increased from 2,220 in 1980 to 13,332 in
1989. The age-standardized incidence rate of ESRD-DM among persons with diabetes
increased more than fivefold, from 38.4 to 201.9 per 100,000 persons (Table 7). Age
differences in incidence rates decreased during this decade. Rates were higher among

















*Per 1,000 persons with diabetes.
FIGURE 7. Age-standardized rate* of hospital discharge for nontraumatic lower-
extremity amputation among persons with diabetes, by sex, race, and year — United
States, 1980–1988
14 June 4, 1993
TABLE 6. Hospital discharge rate for diabetic ketoacidosis as primary diagnosis per
1,000 persons with diabetes, by age group and year — United States, 1980–1988
Year
Age (years) 1980 1981 1982 1983 1984 1985 1986 1987 1988
  ≤44 36.6 39.8 40.3 51.5 58.6 51.7 55.2 49.9 59.3
45–64  5.2  7.1  5.7  4.5  6.9  6.9  5.7  5.2  3.8
  ≥65  4.2  3.6  2.5  3.9  3.6  3.8  4.0  3.9  3.6
Total 10.3 11.0 10.2 12.4 13.7 12.8 12.6 13.6 13.2
Age-adjusted
rate 10.3 11.3 10.4 12.4 14.6 13.4 13.6 12.5 13.4

















*Per 100,000 persons with diabetes.
FIGURE 8. Age-standardized mortality* for diabetic ketoacidosis as underlying cause
of death among persons with diabetes, by race, sex, and year — United States,
1980–1988
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blacks than among whites (Figure 9). Among both races, males had higher rates than
females until 1986, when rates for black females began to exceed those for black
males.
Disability
The number of persons with diabetes who reported that they were limited in activ-
ity increased from 3.1 million in 1983 to 3.3 million in 1989, approximately half of all
persons with known diabetes (Figure 10). This proportion increased with age and
tended to reach a plateau after age 64. In general, age-standardized rates of being
limited in activity were greater among blacks than among whites and among females
TABLE 7. Rate of initiation of treatment for end-stage renal disease due to diabetes
per 100,000 persons with diabetes, by age group and year — United States, 1980–1989
Year
Age (years) 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989
  ≤44 74.2 119.5 149.5 162.8 193.9 204.1 217.7 169.4 213.7 220.9
45–64 42.6  65.6  91.5 105.6 136.6 158.1 143.3 178.1 204.8 215.7
65–74 24.6  49.8  59.2  89.6  82.9  96.1 139.4 147.5 174.6 221.8
  ≥75  8.9  10.1  24.7  28.6  33.0  43.5  44.9  62.4  76.1 106.9
Total 38.4  61.7  83.6 100.3 112.4 127.5 135.2 148.4 176.1 200.2
Age-adjusted















*Per 100,000 persons with diabetes.
FIGURE 9. Age-standardized incidence* of end-stage renal disease with diabetes as
primary cause among persons with diabetes, by race, sex, and year — United States,
1980–1989
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than among males. From 1983 through 1989, rates decreased in all sex-race groups,
except for white males.
Approximately 40% of all persons with diabetes—and 75% of persons with diabe-
tes who reported limitations—reported being limited in their major activity (Figure 10).
About 20% of persons with diabetes reported that they were unable to perform their
major activity.
The number of restricted-activity days among persons with diabetes increased
from 199 million days in 1983 to 233 million days in 1989. During this period, persons
with diabetes averaged 34 restricted-activity days per year; half of these days were
bed-rest days. The average number of total restricted-activity days and bed-rest days
was greater among blacks than whites (Figure 11).
DISCUSSION
Although the overall rate of increase in diabetes prevalence slowed and reached a
plateau in the 1980s, the number of persons known to have diabetes increased by
nearly 900,000 from 1980 through 1989. Because the prevalence of diabetes is associ-
ated with age, the number of persons with diabetes will continue to increase as the
population ages, even if total population size and age-specific prevalence remain con-
stant. Effective intervention strategies for preventing non-insulin-dependent diabetes
mellitus (NIDDM), which accounts for 90%–95% of all prevalent cases, are urgently
needed, particularly among groups at high risk for developing diabetes (e.g., blacks











Unable to Perform Major Activity
Limited in Major Activity
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*In millions; 3-year moving average.
FIGURE 10. Number* of persons with diabetes who report being limited in activity,
limited in major activity, and unable to perform major activity, by year — United
States, 1983–1989
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and other minority groups). These primary prevention strategies should focus on pro-
moting healthful behaviors such as improved diet, exercise, and weight control.
Among persons with diabetes, major CVD accounted for more than half of all
deaths and about one-third of all hospitalizations. Thus, the reduction of CVD risk fac-
tors among persons with diabetes could have a major effect on diabetes-related
morbidity and mortality. Studies on the effectiveness of CVD risk-factor reduction
among diabetic persons are needed. In the absence of such studies, prevention efforts
should promote exercise, weight control, smoking prevention and cessation, hyper-
tension prevention and blood pressure control, and lipid and glycemic control.
Temporal trends in hospital discharge rates varied by discharge diagnosis and
must be interpreted with caution, because Medicare’s implementation of the prospec-
tive reimbursement system in 1983 appears to have influenced hospitalization
practices and disease reporting on discharge records. For example, the rate of LEA
hospital discharges among persons with diabetes increased by >50% in 1983. This
increase was probably due to increased reporting of diabetes among those having
amputations rather than to increased incidence; the inclusion of diabetes as a contrib-
uting cause for LEA results in the assignment of that discharge to a higher
reimbursement group.
The incidence of ESRD-DM increased dramatically in the 1980s. This increase may
have been due to increases both in the incidence of ESRD-DM and in the use of treat-
ment. Recommendations for preventing and slowing the progression of ESRD-DM
among persons with diabetes include annual monitoring for early markers of renal
disease among diabetic persons, controlling hypertension, and identifying and elimi-
nating barriers to preventive care and treatment (13 ).
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*Three-year moving average.
FIGURE 11. Age-standardized average number of restricted activity days and bed
rest days* per person per year among persons with diabetes, by race and year —
United States, 1983–1989
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Many persons with diabetes have some degree of disability. Efforts to describe the
disease burden of diabetes (and other chronic conditions) that do not consider disabil-
ity will greatly underestimate the impact and burden of diabetes and its complications.
Efforts to prevent disability among persons with diabetes should incorporate strate-
gies to reduce the burden of diabetes and its complications, including CVD risk factor
reduction, health promotion, improving access to health-care services and preventive
care, patient and professional education, and incorporation of consensus standards of
care (14 ) into health-care delivery systems. Diabetes control programs in 26 states
and one territory are currently using these and other strategies to reduce the morbid-
ity and mortality associated with diabetes among high-risk groups (e.g., the medically
underserved and minority groups).
Black-white differences in trend were examined because diabetes and its complica-
tions disproportionately affect blacks and other minorities (1,3 ). Although genetic
markers have not been identified for most forms of NIDDM, which accounts for 97% of
incident cases, twin studies, studies of ancestral admixture, and other studies suggest
that genetic factors play a strong role in the development of NIDDM (15-17). Not only
are blacks and other racial/ethnic minorities more likely to develop diabetes, they are
also at greater risk for many of the complications of diabetes (11,18,19). Our surveil-
lance data indicate that blacks have higher rates of diabetes, of mortality with diabetes
and DKA as underlying causes, of hospital discharges with diabetes and DKA as pri-
mary diagnoses, of LEA and ESRD-DM incidence, and of disability. It is unknown
whether this increased risk of complications reflects more severe disease, barriers to
health-care services, including preventive-care services, or the combination of these
and other factors. Prevention efforts should be intensified in this high-risk population.
FUTURE DIRECTIONS
Although national data are available for many of the complications of diabetes,
some important gaps remain. Diabetes is the leading cause of new cases of blindness
among adults in the United States, but recent national data are not available for eye
disease and blindness related to diabetes. Furthermore, although women with diabe-
tes are known to be at increased risk for adverse outcomes of pregnancy, national data
are not available for monitoring pregnancy outcomes among these women, nor are
periodic, national data available on health-care practices and behaviors that could pre-
vent many of the complications of diabetes. Periodic, representative data are also
lacking for minority groups such as Hispanics and Native Americans, who are at in-
creased risk for both diabetes and its complications. CDC is currently exploring
possible data sources to address these important gaps.
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Abstract
Problem/Condition: Neisseria meningitidis  is a leading cause of bacterial meningitis
and septicemia in the United States. Accurate surveillance for meningococcal disease
is required to detect trends in patient characteristics, antibiotic resistance, and sero-
group-specific incidence of disease.
Reporting Period Covered: January 1989 through December 1991.
Description of System: A case of meningococcal disease was defined by the isolation
of N. meningitidis  from a normally sterile site, such as blood or cerebrospinal fluid, in
a resident of a surveillance area. Cases were reported by personnel in each hospital
laboratory in the surveillance areas. The surveillance areas consisted of three counties
in the San Francisco metropolitan area, eight counties in the Atlanta metropolitan
area, four counties in Tennessee, and the entire state of Oklahoma. 
Results: Age- and race-adjusted projections of the U.S. population suggest that ap-
proximately 2,600 cases of meningococcal disease occurred annually in the United
States. The case-fatality rate was 12%. Incidence declined from 1.3/100,000 in 1989 to
0.9/100,000 in 1991. Seasonal variation occurred, with the highest attack rates in Feb-
ruary and March and the lowest in September. The highest rates of disease were
among infants, with 46% of cases affecting those ≤2 years of age. Males accounted for
55% of total cases, with an incidence of 1.2/100,000, compared with 1.0/100,000
among females (relative risk (RR) = 1.3, 95% confidence interval (CI) 1.0–1.6). The inci-
dence was significantly higher among blacks (1.5/100,000) than whites (1.1/100,000)
(RR = 1.4 [95% CI 1.1–1.8]). Serogroup B caused 46% of cases and serogroup C, 45%.
Thirty-eight percent of isolates were reported to be resistant to sulfa; none were re-
ported to be resistant to rifampin.
*Members of the Meningococcal Disease Study Group are Katherine A. Deaver, Richard Pierce,
M.P.H., and Robert Weaver, M.D., Ph.D., CDC; Gretchen Anderson, M.P.H., Pam Daily, M.P.H., Kevin
Kraus, Bharat Pattni, M.D., M.P.H., Elizabeth Stone, M.P.H., and Arthur L. Reingold, M.D., San Francisco
(California) Department of Health; Margaret Rados, Jo Taylor, R.N., Louis Lefkowitz, M.D., Department
of Preventive Medicine, Vanderbilt Medical Center, Nashville, TN; Pam Archer, M.P.H., Laura M. K.
Smithee, M.S., Jane Strack, Gregory R. Istre, M.D., Oklahoma State Department of Health, Oklahoma
City, OK; Christopher Harvey, M.P.H., Tina Stull, M.D., Monica Farley, M.D., and David Stephens, M.D.,
Emory University Department of Medicine, Atlanta, GA.
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Interpretation: The decline in incidence of meningococcal disease from 1989 through
1991 cannot be explained by any change in public health control measures; this trend
should be monitored by continued surveillance. The age, sex, and race distribution
and seasonality of cases are consistent with previous reports. The proportion of N.
meningitidis  isolates resistant to sulfa continues to be substantial. A relatively small
proportion of cases is potentially preventable by the use of the currently available
polysaccharide vaccine, which induces protection against serogroups A, C, Y, and
W135 and is effective only for persons >2 years of age.
Actions Taken: Current recommendations against the use of sulfa drugs for treatment
or prophylaxis of meningococcal disease unless the organism is known to be sensitive
to sulfa should be continued. Since resistance to rifampin is rarely reported, it contin-
ues to be the drug of choice for prophylaxis. The development of vaccines effective for
infants and vaccines inducing protection against serogroup B would be expected to
have a substantial impact on disease.
INTRODUCTION
Neisseria meningitidis  is a leading cause of bacterial meningitis and septicemia in
the United States (1 ). Although epidemic meningococcal disease continues to be a
major public health problem in sub-Saharan Africa and other parts of the developing
world, most disease in the United States is sporadic. Approximately half the cases in
the United States are caused by serogroup B, with the highest attack rates in children
<2 years of age (2 ). Efforts to control disease have been limited because the currently
available quadrivalent meningococcal polysaccharide vaccine is effective only against
serogroups A, C, Y, and W135 and is poorly immunogenic in children <2 years of age
(3 ). Accurate surveillance for meningococcal disease is required to detect trends in a)
patient characteristics, which may allow groups at higher risk of disease to be identi-
fied; b) antibiotic resistance, which influences the choice of antimicrobial agents for
treatment and prophylaxis; and c) serogroup-specific incidence of disease, which in-
fluences the potential applications of the quadrivalent meningococcal polysaccharide
vaccine. This report summarizes information from a laboratory-based surveillance
system for invasive meningococcal disease conducted in a large U.S. population from
January 1989 through December 1991.
METHODS
Laboratory-based surveillance, using methods previously described (1,2 ), was
conducted in an aggregate population of 10.3 million persons (4.1% of the U.S. popu-
lation), consisting of residents of three counties in the San Francisco metropolitan
area, eight counties in the Atlanta metropolitan area, four counties in Tennessee, and
the entire state of Oklahoma. Seventy-one percent of residents in the surveillance ar-
eas were white and 18% were black, compared with 80% and 12%, respectively, of the
U.S. population. Surveillance was initiated in November 1988 and is ongoing; how-
ever, only cases reported from January 1, 1989, through December 31, 1991, are
included in this report.
22 June 4, 1993
A case of meningococcal disease was defined by the isolation of Neisseria men-
ingitidis  from a normally sterile site, such as blood or cerebrospinal fluid (CSF), in a
resident of a surveillance area. Cases were reported to surveillance workers by con-
tacts in each hospital laboratory in the surveillance areas. A case report form with
information about age, sex, race, outcome, and clinical syndrome of the patient, as
well as the site of isolation, serogroup, and antibiotic sensitivities of the organism,
was completed for each identified case. Hospital laboratory directors were asked to
send N. meningitidis  isolates to CDC for serogrouping; 65% of case isolates were re-
ceived at CDC. To evaluate the sensitivity of reporting, hospitals were periodically
audited by review of microbiology records. The audit completed in January 1990 iden-
tified 91 N. meningitidis  cultures from sterile sites. Eighty-eight had been reported
through the surveillance system, for a sensitivity of 96%.
Because race is a likely risk marker for meningococcal disease, data were analyzed
by race, and the projected national incidence and annual number of cases based on
incidence among surveillance area residents were adjusted for race. Races other than
white or black were designated in <5% of records; therefore, only results of stratifica-
tion by white and black race are reported.
Rates of disease were calculated by using 1990 population data from the U.S. Bu-
reau of the Census. Fisher’s exact test was used to assess statistical significance.
RESULTS
In the years 1989 through 1991 in the four surveillance areas, 332 cases of menin-
gococcal disease were detected, for an average incidence of 1.1/100,000 population
during this period. Based on this rate, when the data were adjusted for differences in
racial distribution between the surveillance area population and the U.S. population,
an estimated 2,600 cases of meningococcal disease occurred annually in the United
States. The incidence was 1.3/100,000 in 1989, 1.0/100,000 in 1990, and 0.9/100,000 in
1991; this trend toward decreasing incidence with time was statistically significant
(chi-square for linear trend, p = 0.019). Seasonal variation occurred, with the highest
attack rates in February and March and the lowest in September (Figure 1). Of the 314
cases for which outcome information was available, 36 persons died, for a case-fatal-
ity rate of 12%. The case-fatality rate did not vary by sex, race, age, clinical syndrome,
serogroup, or site of isolation of the organism.
The highest rates of disease occurred in infants <1 year of age, with a peak inci-
dence of 26.4/100,000 population in infants <4 months of age (Figure 2). Twenty-nine
percent of cases were in infants <1 year of age, 46% in children ≤2 years of age, and
25% in persons ≥30 years of age. The age distribution of cases did not vary by sex or
race. Males accounted for 55% of total cases, with an incidence among males of
1.2/100,000, compared with 1.0/100,000 among females (RR = 1.3; 95% CI, 1.0–1.6). The
incidence was significantly higher among blacks (1.5/100,000) than whites
(1.1/100,000; RR = 1.4; 95% CI, 1.1–1.8).
The average annual incidence of disease for the period 1989 through 1991 varied
among the surveillance areas, with a peak of 1.3/100,000 in the San Francisco metro-
politan area and a low of 0.6/100,000 in Oklahoma (p<0.001). The incidence was higher
among blacks than whites in all surveillance areas except Tennessee (Figure 3). The
highest annual incidence, 1.9/100,000, occurred in San Francisco in 1989. An increased
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rate of disease in the <2-year-old age group accounted for most of the increase in
overall rate in this area during 1989. The attack rate in the <2-year-old age group in the
San Francisco surveillance area was 23.0/100,000 in 1989, compared with 5.1/100,000
in 1990 and 10.2/100,000 in 1991. The cases among children ≤2 years old were not
temporally clustered, and the serogroup distribution was similar to that reported for
this age group in 1990 and 1991.
Meningitis, defined as N. meningitidis  isolated from CSF and/or meningitis re-
ported as the clinical syndrome on the case report form, accounted for 58% of cases,
with an incidence of 0.6/100,000 population. The case-fatality rate for meningitic dis-
ease was 13% (25/192), which does not differ significantly from the case-fatality rate of
9% (13/140) for disease not meeting the above case definition for meningitic disease.
The incidence of meningitic disease did not vary significantly by race; however, men-
ingitis represented a higher proportion of total disease among whites (61%) than
blacks (47%) (p<0.05). The incidence of nonmeningitic disease declined after 12
months of age until age 20, when a secondary increase in incidence was seen that
continued through the ≥60 age group (Figure 4). Nonmeningitic disease accounted for
63% of total disease in persons ≥30 years.
Meningitis was reported as the clinical syndrome on the case report form in 57% of
cases and primary bacteremia in 49%. Other syndromes were much less common,
with pneumonia reported in 4% of cases, otitis media in 2%, cellulitis in 0.6%, and
arthritis in 0.3%. N. meningitidis  was isolated from blood in 66% of cases, CSF in 51%,



























FIGURE 1. Seasonal variation in incidence of meningococcal disease, selected U.S.
areas, 1989–1991
24 June 4, 1993
joint fluid in 1%, and pleural and peritoneal fluid in 0.3% each. More than one clinical
syndrome or site of isolation was reported for some cases. The case-fatality rate when
the organism was isolated from blood (regardless of whether it was also isolated from
another site) was 11.5% (25/218); the case-fatality rate when the organism was iso-
lated only from CSF was 9.3% (10/110).
A total of 217 isolates were serogrouped at CDC; serogroup information was col-
lected locally and recorded on the case report form for 179. Serogroup data were
available from either or both sources for 261 (79%) of cases. For 132 isolates, sero-
group information was reported from both sources; the sources agreed in 118 (89%)
cases. When a discrepancy occurred, the CDC results were used. The proportion of
cases with serogroup information did not differ by race.
Serogroup B organisms accounted for 46% and serogroup C organisms for 45% of
isolates for which serogroup information was available. W135, Y, and nontypeable
serogroups accounted for 3%, 2%, and 2% of isolates, respectively. One isolate was
reported to be serogroup A, and two others were reported as “other” serogroup;
these isolates were not submitted to CDC for serogrouping. The estimated serogroup-
specific incidences were 0.5/100,000 population for both serogroups B and C.
Serogroup B disease accounted for 51% of disease among whites but for only 27%
among blacks (p<0.01). A significantly higher incidence of group C disease
(1.0/100,000 vs. 0.4/100,000 [p<0.01]) and a similar (not significantly different)


















































FIGURE 2. Incidence of meningococcal disease, by age group, selected U.S. areas,
1989–1991
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incidence of group B disease (0.4/100,000 vs. 0.6/100,000; p = 0.4) occurred among
blacks compared with whites.
A significantly higher proportion of group C disease occurred in older age groups,
with 69% of group C disease, compared with 37% of group B disease, in persons >2
years of age (p<0.001) (Table 1). The incidence of group C disease varied by surveil-
lance area, with rates of 0.4/100,000 and 0.2/100,000 in Tennessee and Oklahoma,
compared with a rate of 0.7/100,000 both in Atlanta and San Francisco. Rates of group
B disease varied less by surveillance area (Figure 5).
The proportion of meningitic and nonmeningitic disease caused by serogroups B
and C was similar. Serogroups other than B and C accounted for four (44%) of nine
pneumonia cases, compared with only 19 (6%) of 323 cases of all other syndromes
(p=0.002). Twenty-eight (38%) of the 73 isolates for which sulfa sensitivity was re-
ported were reported to be resistant. Sulfa resistance did not vary by serogroup. None
of the 42 isolates for which rifampin sensitivity was reported were found to be resis-
tant.
DISCUSSION
The average annual rate of disease, 1.1/100,000 population, detected by this labora-
tory-based surveillance system in an aggregate population of 10 million persons from
1989 through 1991 was slightly lower than the rate of 1.3/100,000 population detected
by a similar surveillance system in an aggregate population of 34 million in 1986 (2 ).





























FIGURE 3. Incidence of meningococcal disease, by race, selected U.S. areas, 1989–1991
26 June 4, 1993
This decrease in the rate of disease cannot be attributed to public health control
measures adopted during this period. The decline in incidence therefore could repre-
sent a natural fluctuation in disease incidence or could indicate a change in the
occurrence of disease, possibly due to factors such as changes in the population’s
susceptibility to disease or in the organism’s prevalence or virulence. The rate of men-
ingococcal disease in the United States, as reported by CDC through the National
Notifiable Diseases Surveillance System, also declined over a similar period, suggest-
ing that the decrease was not limited to the geographic areas included in the
laboratory-based surveillance system. The rate of meningococcal disease reported by
CDC decreased from 1.2/100,000 population in 1988 to 1.1/100,000 population in 1989,
1.0/100,000 population in 1990, and 0.8/100,000 population in 1991 (chi-square test for
linear trend, p<0.001) (4 ). Continued surveillance for meningococcal disease is
needed to determine the importance of this trend.
The age, sex, and race distribution and seasonality of cases reported by this labo-
ratory-based surveillance system are consistent with previous reports. The higher
attack rate among males, who accounted for 55% of total cases, was not found in
1986; however, higher rates of meningococcal meningitis in males have been reported
previously (5,6 ). The 1986 laboratory-based surveillance system detected a higher
rate of invasive meningococcal disease among blacks (2 ), and a report of bacterial
meningitis passive surveillance data from 1978 through 1981 also noted higher rates
of meningococcal meningitis among blacks compared with whites (5 ). Previous

























FIGURE 4. Incidence of meningitic and nonmeningitic meningococcal disease, by age
group, selected U.S. areas, 1989–1991
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studies have reported a higher incidence of meningococcal disease among blacks
than whites (2,5 ). Reasons for this difference are unclear; however, race is likely a risk
marker rather than a risk factor for meningococcal disease. The race-specific variation
in disease rates may reflect differences in factors such as household crowding, urban
residence, or exposure to tobacco smoke. Risk markers may be useful for identifying
groups to target with prevention efforts and may also suggest potential risk factors to
investigate in future studies.
























FIGURE 5. Incidence of meningococcal disease, by serogroup, selected U.S. areas,
1989–1991
TABLE 1. Annual incidence and estimated number of cases of serogroups B and C










      ≤2 years 7.5 3.1   822   382
   3–5 years 0.58 1.9    62   203
 6–17 years 0.20 0.50    83   208
18–29 years 0.12 0.25    58   117
  ≥30 years 0.21 0.19   288   268
All ages 0.51 0.46 1,313 1,178
*Incidence reported as cases/100,000 population per year.
28 June 4, 1993
Serogroups B and C accounted for approximately equal proportions of disease;
however, only 30% of cases in the ≤2-year-old age group were due to serogroup C.
Although serogroup C represented a higher proportion of total cases in older age
groups, the incidence of disease in these age groups was lower; thus, the total esti-
mated number of cases of group C disease in the >2-year-old age group is relatively
small. Even if vaccination were 100% effective against group C disease and all persons
>2 years of age were routinely vaccinated with the polysaccharide vaccine, only 33%
of meningococcal disease would be prevented. At current rates of disease, routine
vaccination is unlikely to be a cost-effective preventive measure. However, vaccination
of populations with clusters of disease (with high incident rates) is warranted, and
further evaluation of the potential role of immunization for group C disease is under
way. Development of vaccines that protect against serogroup B disease and are im-
munogenic in the age groups at highest risk of disease might improve the
effectiveness of vaccination for meningococcal disease.
In 1986, a reported 61% of isolates were resistant to sulfa, with a significantly
higher rate of resistance among group C compared with group B isolates (2 ). In con-
trast, in the present study the rate of resistant to sulfa was 37%; no difference was
detected in resistance patterns by serogroup. Variation in reported sulfa resistance
was also identified in data received through the CDC passive surveillance system from
1970 through 1980; the reported proportion of sulfa resistance varied from 12% to
67%, although it did not exceed 16% after 1974 and varied only from 11% to 16% from
1974 through 1980 (7 ). The prevalence of sulfa-resistant N. meningitidis is consis-
tently high enough to warrant continuation of current recommendations against the
use of sulfa drugs for treatment or prophylaxis of meningococcal disease unless the
organism is known to be sensitive to sulfa. Since resistance to rifampin is rarely re-
ported, it continues to be the drug of choice for prophylaxis.
The highest rates of both meningitic and nonmeningitic meningococcal disease oc-
curred in infants <1 year of age. A secondary peak was noted in nonmeningitic disease
only after age 20, with an increase in rate that continued through persons ≥60 years of
age (Figure 5). This secondary peak in incidence of nonmeningitic meningococcal dis-
ease was noted previously in a report of a laboratory-based surveillance system for
invasive disease due to N. meningitidis  (1 ). This report differed from the present
study in noting a significantly higher case-fatality rate for nonmeningitic, compared
with meningitic, meningococcal disease (17% vs. 12%).
Efforts to develop a serogroup B vaccine and protein conjugate C vaccines that
would be immunogenic in infants are ongoing (8-10 ). Such vaccines, if incorporated
into routine childhood vaccination schedules, would be expected to have a substantial
impact on meningococcal disease, which remains an important cause of morbidity
and mortality (an estimated 2,600 cases per year, 12% of which are fatal) in the United
States.
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